Description
Main compound administered orally
Anti-PD-1/PD-L1 immunotherapy has become a key strategy in the fight against cancer, aimed at reprogramming or activating the body’s anti-tumor immune response to destroy tumor cells without harming healthy cells.
WAVEIMMUNE compounds are small-molecule PD-L1 inhibitors that have shown promising results in vitro and in vivo:
•AliPD1 is the lead compound in the series
•In vitro binding to the target
•Significant reduction in tumor volume in vivo in colorectal carcinoma
Partnership: Startups Seeking Funding
IP: PCT, Priority Date: June 30, 2024
Currently:
In vivo proof of concept in other models
Studies on the mechanism of action